Michael Schweizer, MD, discusses the mechanism of action of mevrometostat and early-phase data with the agent in mCRPC.
Michael Schweizer, MD
Advertisement
Articles by Michael Schweizer, MD
Michael Schweizer, MD, discusses the results of the HERO trial in prostate cancer.
Michael Schweizer, MD, discusses the rationale for the phase 3 CARD trial in metastatic castration-resistant prostate cancer.
Michael Schweizer, MD, discusses the role of olaparib in patients with non–BRCA-mutant metastatic castration-resistant prostate cancer.
Advertisement
Latest Updated Articles
Dr. Schweizer on the Rationale for the CARD Trial in mCRPCDecember 21st 2020
Dr. Schweizer on the Role of Olaparib in Non–BRCA-Mutant mCRPCDecember 7th 2020
Advertisement
Advertisement
Trending on OncLive
1
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
2
From Toilet Cleaner to Thoracic Oncologist and Patient: How Ross Camidge Built a Life Worth Loving
3
Breast Cancer Experts Spotlight Practice-Informing and Thought-Provoking Data From ASCO 2026
4
FDA Grants Priority Review to Giredestrant for ER-Positive Early Breast Cancer
5